- Rating
- 3(+1)
- Confidence
- 3(+1)
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper presents IgSeven for antibody design. It represents CDR backbone shapes using a finite vocabulary of structural motifs. Ig7G generates antibody sequences, structures, and docking poses under these shape conditions. Ig7O uses Bayesian optimization to search for CDR shape combinations based on property feedback.
Critical strengths
- Support for multiple tasks. The framework supports co-folding, inverse folding, antibody generation with specified CDR shapes, and optimization with one or multiple objectives. These tasks share the same conditioning interface. This range of applications is a strength of the work.
- Strong co-folding performance. The method achieves strong performance in epitope-constrained co-folding. These results demonstrate its ability to capture antibody structures and interactions with antigens. They also support the rationale behind the method design.
Critical weaknesses
- The central motivation needs stronger evidence. Figure 1 shows that cluster-assigned CDRs have higher amino acid recovery than unassigned CDRs. This correlation does not establish that conditioning generation on recurrent shapes improves design quality. Loop type, length, training-data frequency, and prediction difficulty may affect both cluster assignment and AAR. Higher sequence recovery also does not establish stronger antigen binding. The authors present this observation as motivation. However, further evidence is needed to show that the restricted structural interface improves design efficiency while preserving design capacity.
- The method and experimental protocols are difficult to follow. The paper describes the architecture and provides optimization pseudocode. However, the inputs, control channels, and sampling settings for each task remain unclear. The descriptions of co-folding and inverse folding mainly specify their inputs and outputs. They do not clearly state which sequence, structural, and latent controls are used. The paper also needs to explain how known sequences or structures are preserved during generation.
- CDR novelty and diversity are not established. The fixed frameworks, shape vocabulary, and reference-recovery objectives may favor designs close to existing antibodies. The paper does not quantify the novelty of generated CDRs or their similarity to training examples. These analyses are particularly important for CDR-H3. Reusing known motifs does not by itself imply memorization. Sequence and structural novelty analyses are needed to assess whether the restricted space supports diverse and novel designs.
Questions for authors
- Independent validation of designed complexes. Could the authors provide validation using methods that were not used during optimization? Replicated MD simulations in explicit solvent could provide additional evidence. Comparisons with matched baselines could assess CDR stability and the persistence of interface contacts. Such results would complement the current scores, although they would not directly establish binding affinity.
- Nanobody interface energy. For nanobodies, the best Rosetta energy from discrete search is −32.681. Complexa Best-of-N achieves −42.792. Could the authors explain why interface energy worsens while AAR and RMSD improve? Per-target results and energy curves across evaluation budgets would help identify the cause.
2 comments
Thanks for the additional experiment. This addresses my last concern. I'm willing to raise my score to 3. Please add the results to the revised version.
The authors have addressed most of my concerns. However, I'm still concerned about the novelty and diversity of the generated sequences. Could the authors provide the novelty and diversity of other methods/baselines to compare with?